NCT00298766View on ClinicalTrials.gov

Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

July 31, 2009

Study Completion Date

September 30, 2009

Conditions
Amyloidosis
Interventions
DRUG

VELCADE

"Once weekly at: 0.7, 1.0, 1.3 or 1.6 mg/m2~Or~Twice-weekly at: 0.7, 1.0, or 1.3 mg/m2"

Trial Locations (4)

10017

MSKCC, New York

30322

Winship Cancer Center - Emory Clinic School of Medicine, Atlanta

90049

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles

02118

Boston Medical Center, Boston

Sponsors
All Listed Sponsors
collaborator

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

lead

Millennium Pharmaceuticals, Inc.

INDUSTRY